The company will use the funds to advance its brain shuttle platform that delivers RNAi therapies across the blood-brain ...
Brings total funds raised to $60 million since launch, months after its seed funding announcement in October 2025Appoints Arno de Wilde, Philip ...
Series A financing will be used to advance Aerska's brain shuttle technology to improve the delivery of RNA interference therapeutics for neurological diseases Financing was co-led by EQT Life ...
Roche is continuing its return to the RNA space by paying $200 million for the worldwide license to one of SanegeneBio’s ...
Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi ...
SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...
Please provide your email address to receive an email when new articles are posted on . RNA therapeutics lowered all-cause mortality, increased 6-minute walk distance and improved quality of life. RNA ...
Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results